Aurel Capital works with researchers, scientists, clinicians and physician-scientists on ideas with the potential to improve human health.

Not every breakthrough becomes a company.

Some become patents.

Some become licensed technologies.

Some improve standards of care.

Some become the foundation for future discoveries.

Whatever the outcome, we believe significant research deserves thoughtful strategy and the right ecosystem to maximize its impact.

Three things get decided before any money arrives, whichever way it goes.

Who owns the intellectual property. Under most institutional policies, that is your institution rather than you, and faculty agreements usually assign inventions automatically.

What you have already published, and when. A paper that goes out before a patent is filed can quietly end the patent.

What your technology transfer office will want in return. Its duty runs to the institution, so it is a negotiation rather than a form.

The money itself is usually not investment. For most work at this stage the right first step is non-dilutive. BIRAC's BIG scheme funds individuals and young companies up to ₹50 lakh over 18 months and is open to scientists, faculty and research scholars, and DBT and ICMR run parallel routes. Taking equity money too early, against thin evidence, sets a price the science cannot grow into.

How We Collaborate





- Working out which path the research is actually on: a grant, a licence, a company, or more evidence first
- Sequencing publication and filing so disclosure does not cost you the patent
- Handling the technology transfer conversation as a negotiation
- Evaluating translational, regulatory, commercialization, licensing and partnership pathways
- Working alongside academic institutions, hospitals, industry partners and investors
- Contributing to research initiatives, publications and investment theses

Who We Collaborate With

- Academic researchers, principal investigators, postdoctoral researchers and hospital-based researchers
- Physician-scientists and clinicians with a result and no company
- Anyone at the point where the next decision is about money, IP or publication, and there is nobody obvious to ask

You do not need a company, a deck, or a co-founder. We will tell you which of those paths your work is on, and we will say so plainly when the answer is that you do not need us yet.

We'd like to hear what you're building, researching or exploring.

Send us a short note about yourself, where you've got to, and the decision in front of you. A paragraph is plenty. Then schedule a conversation and we'll take it from there.

Email: [email protected]

Schedule a conversation: calendly.com/partners-aurelcap/30min

📌 Opportunity - Researchers, Scientists & Clinicians (Mumbai)
🏢 Aurel Capital
📍 Mumbai